Odabas H, Ozdemir N, Isik M, Abali H, Oksuzoglu B, Kos T, Civelek B, Babacan A N, Dogan U, Zengin N
Ankara Numune Education and Research Hospital, Department of Oncology, Ankara, Turkey.
J BUON. 2011 Jul-Sep;16(3):460-3.
To evaluate the efficacy and the safety of FOLFIRI-bevacizumab (B) in the 2nd line therapy of metastatic colorectal carcinoma (MCRC).
Between March 2006 and July 2009 35 patients with MCRC were treated with 2nd line therapy FOLFIRI- B (irinotecan 180 mg/m(2) D1, folinic acid 200 mg/m(2) D1, 5-fluorouracil/5 FU 400 mg/m(2) bolus D1, followed by 5 FU 2600 mg/m(2) 46-h continuous infusion, and bevacizumab 5 mg/kg D1, every 2 weeks) Their data were collected and analysed.
The patient median age was 54 years (range 36-75). One patient (2.8%) had received oxaliplatin-based adjuvant chemotherapy and 33 patients (94.3%) were exposed to oxaliplatin during first line chemotherapy for MCRC. The median follow up period was 12.2 months (range 1.5-37.9). Complete remission (CR) was achieved in 5.7% of the patients and the sum of CR and partial remission (PR) was 11.4%. Disease control (CR+PR+stable disease/SD) was registered in 74.3% of the patients. During follow up, progression (PD) was seen in 32 (91.4%) patients and 23 (65.7%) patients had died. The median progression free survival (PFS) was 7.4 months (95%CI 5.5-9.3) and the median overall survival (OS) 13 months (95%CI 8.8-17.2). Grade 3-4 toxicity requiring delay of chemotherapy was observed in 12 (34.3%) patients with 10 patients (28.6%) having neutropenia and 2 (5.7%) diarrhea.
FOLFIRI-B may be an efficient and safe choice in the 2nd line treatment of patients with MCRC previously treated with oxaliplatin.
评估FOLFIRI方案联合贝伐单抗（B）用于转移性结直肠癌（MCRC）二线治疗的疗效与安全性。
2006年3月至2009年7月期间，35例MCRC患者接受了二线治疗FOLFIRI-B方案（伊立替康180mg/m²第1天，亚叶酸钙200mg/m²第1天，5-氟尿嘧啶/5-FU 400mg/m²静脉推注第1天，随后5-FU 2600mg/m²持续输注46小时，贝伐单抗5mg/kg第1天，每2周一次）。收集并分析他们的数据。
患者中位年龄为54岁（范围36-75岁）。1例患者（2.8%）接受过以奥沙利铂为基础的辅助化疗，33例患者（94.3%）在MCRC一线化疗期间接受过奥沙利铂治疗。中位随访期为12.2个月（范围1.5-37.9个月）。5.7%的患者达到完全缓解（CR），CR与部分缓解（PR）之和为11.4%。74.3%的患者疾病得到控制（CR+PR+疾病稳定/SD）。随访期间，32例（91.4%）患者出现疾病进展（PD），23例（65.7%）患者死亡。中位无进展生存期（PFS）为7.4个月（95%CI 5.5-9.3），中位总生存期（OS）为13个月（95%CI 8.8-17.2）。12例（34.3%）患者出现需要延迟化疗的3-4级毒性反应，其中10例（28.6%）为中性粒细胞减少，2例（5.7%）为腹泻。
FOLFIRI-B方案可能是先前接受过奥沙利铂治疗的MCRC患者二线治疗的有效且安全的选择。
